Assessment of Stress, Depression and Anxiety in Healthcare Caring for Patients With COVID-19
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04631497|
Recruitment Status : Recruiting
First Posted : November 17, 2020
Last Update Posted : November 17, 2020
|Condition or disease||Intervention/treatment|
|Depression||Diagnostic Test: test|
Every day medical staff working in very difficult conditions of intensive care. The COVID-19 virus outbreak has set another difficult task for doctors and nurses who have previously had a lot of contact with the death of their patients. The appearance of the COVID-19 virus and, above all, the inability to effectively treat the infection causes an additional psychological stimulus in medical personnel.
The aim of the study is to assess the occurrence of psychiatric disorders in medical personnel dealing with patients suffering from COVID-19 using various psychological tests.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Assessment of Stress, Depression and Anxiety in Healthcare Caring for Patients With COVID-19|
|Actual Study Start Date :||July 1, 2020|
|Estimated Primary Completion Date :||December 31, 2020|
|Estimated Study Completion Date :||December 31, 2021|
The study will cover employees of the Intensive Care Unit - nurses and doctors working with patients with COVID-19 infection. Test takers will be over the age of 18 and under the age of 70, female and male.
Diagnostic Test: test
- Depression [ Time Frame: 1 month ]
Beck's test the BDI-II contains 21 questions, each answer being scored on a scale value of 0 to 3. Higher total scores indicate more severe depressive symptoms. The standardized cutoffs used differ from the original:
0-13: minimal depression 14-19: mild depression 20-28: moderate depression 29-63: severe depression
- Stress [ Time Frame: 1 month ]
Perceived Stress Scale (PSS)
The PSS predicts both objective biological markers of stress and increased risk for disease among persons with higher perceived stress levels. For example, those with higher scores (suggestive of chronic stress) on the PSS fend worse on biological markers of aging, cortisol levels, immune markers, depression, infectious disease,wound healing, and prostate-specific antigen levels in men. PSS scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 & 4 = 0) to the four positivelystated items (items 4, 5, 7, & 8) and then summing across all scale items. A short 4 item scale can be made fromquestions 2, 4, 5 and 10 of the PSS 10 item scale.
- Deal with Stress [ Time Frame: 1 month ]COPE test It is a self-written tool consisting of 60 statements, to which the respondent responds on a 4-point scale. It allows the assessment of 15 strategies for responding to stressful situations.
- Stress 2 [ Time Frame: 1 month ]the scale of the fascination with death The Death Obsession Scale (DOS) was made by Abdel-Khalek. It was intended to be a main component in the death distress const.ruct: death anxiety, death depression, and death obsession. The DOS assesses a multidimensional trait. It is responded to on a five-point Likert-type rating scale as follows: No (1), A little (2), A fair amount (3), Much (4) and Very much (5). The total score can range from 15 to 75.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04631497
|Contact: Tomasz Skladzien, Ph.D. M.D||+48506602250 ext +email@example.com|
|Contact: Tomasz Skladzien, Ph.D. M.D.||+48506602250 ext +firstname.lastname@example.org|
|University Hospital in Cracow||Recruiting|
|Kraków, Poland, 31-501|
|Contact: Tomasz Skladzien, PhD 506602250 ext +48 email@example.com|
|Principal Investigator:||Tomasz Skladzien, Ph.D. M.D.||Jagiellonian University|